Exelixis and Genentech Collaborate on Novel Therapeutics

Exelixis, Inc. announced that it has signed a collaboration agreement with Genentech for the discovery and development of therapeutics to target cancer, inflammatory diseases, and tissue growth and repair. The collaboration combines the intellectual property and biological capabilities of both companies to target proteins and genes that are involved in cell proliferation and differentiation. Under the collaboration, Genentech will primarily focus on generating antibodies to proteins provided by Exelixis, and the companies will jointly assess their utility in a variety of cancer, inflammation and tissue repair models.

()a href="http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-03-2005/0003774619&EDATE=" target="_blank">PR Newswire